Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children
| Status: | Completed |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 5 - 13 |
| Updated: | 11/16/2017 |
| Start Date: | January 2012 |
| End Date: | July 2017 |
This project examines how seizures, and abnormal brain activity, affect language skill in
children with Benign Childhood Epilepsy with Centro-Temporal Spikes (BECTS). BECTS is a
common type of childhood epilepsy, and while BECTS patients stop having seizures by their
late teenage years, many studies have shown that these children have language problems that
may lead to academic and social difficulties. Using standardized language testing, monitoring
of brain activity, and MRI brain imaging, this project aims to determine what particular
combination of BECTS symptoms put children most at risk for language problems and whether
treatment with anti-epileptic medications may be helpful.
children with Benign Childhood Epilepsy with Centro-Temporal Spikes (BECTS). BECTS is a
common type of childhood epilepsy, and while BECTS patients stop having seizures by their
late teenage years, many studies have shown that these children have language problems that
may lead to academic and social difficulties. Using standardized language testing, monitoring
of brain activity, and MRI brain imaging, this project aims to determine what particular
combination of BECTS symptoms put children most at risk for language problems and whether
treatment with anti-epileptic medications may be helpful.
Benign Childhood Epilepsy with Centro-Temporal Spikes (BECTS), an extremely common type of
childhood epilepsy, is traditionally assumed to have a benign course, but recent studies have
shown that cognitive function, especially language, is often impaired in BECTS patients.
However, it is not clear whether ithe seizures, the centrotemporal spikes (CTS), or other
factors cause the negative cognitive consequences that may impact school performance and
social interaction. BECTS patients have scattered seizures but very frequent CTS, and may be
suffering with undiagnosed cognitive and language deficits. This suggests a causal role for
CTS that has not yet been investigated in detail. This project will examine the impact of
seizures and CTS on neurocognitive function in BECTS patients, at diagnosis and after one
year. We will gather critical information regarding the effect of the anti-epileptic
medication levetiracetam on CTS, which will inform a future Phase III clinical trial aimed at
eliminating CTS and improving long term outcome.
This study will explore the interactions between CTS, seizures and neuropsychological
outcomes using Functional MRI of language in order to decipher changes in neural circuitry
that underlie language deficits found in children with BECTS. Using standardized
neuropsychological testing and fMRI at the time of diagnosis, this study will first
characterize the nature and incidence of language problems in children with BECTS, separating
the effects of CTS and seizures. It is expected that children with BECTS will perform below
normative standards on tests of language skill, accompanied by aberrations in the neural
circuitry supporting language processing as tested with fMRI. These data will also make it
possible to characterize which children with BECTS are most at risk for language problems, by
taking into account contributing factors such as number of seizures, age of onset, and
frequency and lateralization of CTS.
The proposed exploratory clinical trial will also provide key information needed to properly
design and conduct a future double blind Phase III randomized clinical trial (RCT) children
aimed at improving language outcome through elimination of CTS. Using an open-label
dose-ranging design and 1-year follow up, we will determine the best dose of levetiracetam to
control seizures, eliminate CTS and be well tolerated. We will also examine the extent of
changes in language function and neural circuitry of language with 1-year follow-up
neuropsychological testing and fMRI in LEV-treated and untreated BECTS compared to controls
(which will document the natural history of neuropsychological function in untreated BECTS
children and give additional information about the effect of LEV). The current study will
provide crucial information for a future double blind RCT that will the compare the selected
dose of levetiracetam to carbamazepine (the current standard of care) in BECTS. This would
change clinical practice by demonstrating the need for AED treatment in BECTS to eliminate
CTS, in turn improving long term language and cognitive outcome.
childhood epilepsy, is traditionally assumed to have a benign course, but recent studies have
shown that cognitive function, especially language, is often impaired in BECTS patients.
However, it is not clear whether ithe seizures, the centrotemporal spikes (CTS), or other
factors cause the negative cognitive consequences that may impact school performance and
social interaction. BECTS patients have scattered seizures but very frequent CTS, and may be
suffering with undiagnosed cognitive and language deficits. This suggests a causal role for
CTS that has not yet been investigated in detail. This project will examine the impact of
seizures and CTS on neurocognitive function in BECTS patients, at diagnosis and after one
year. We will gather critical information regarding the effect of the anti-epileptic
medication levetiracetam on CTS, which will inform a future Phase III clinical trial aimed at
eliminating CTS and improving long term outcome.
This study will explore the interactions between CTS, seizures and neuropsychological
outcomes using Functional MRI of language in order to decipher changes in neural circuitry
that underlie language deficits found in children with BECTS. Using standardized
neuropsychological testing and fMRI at the time of diagnosis, this study will first
characterize the nature and incidence of language problems in children with BECTS, separating
the effects of CTS and seizures. It is expected that children with BECTS will perform below
normative standards on tests of language skill, accompanied by aberrations in the neural
circuitry supporting language processing as tested with fMRI. These data will also make it
possible to characterize which children with BECTS are most at risk for language problems, by
taking into account contributing factors such as number of seizures, age of onset, and
frequency and lateralization of CTS.
The proposed exploratory clinical trial will also provide key information needed to properly
design and conduct a future double blind Phase III randomized clinical trial (RCT) children
aimed at improving language outcome through elimination of CTS. Using an open-label
dose-ranging design and 1-year follow up, we will determine the best dose of levetiracetam to
control seizures, eliminate CTS and be well tolerated. We will also examine the extent of
changes in language function and neural circuitry of language with 1-year follow-up
neuropsychological testing and fMRI in LEV-treated and untreated BECTS compared to controls
(which will document the natural history of neuropsychological function in untreated BECTS
children and give additional information about the effect of LEV). The current study will
provide crucial information for a future double blind RCT that will the compare the selected
dose of levetiracetam to carbamazepine (the current standard of care) in BECTS. This would
change clinical practice by demonstrating the need for AED treatment in BECTS to eliminate
CTS, in turn improving long term language and cognitive outcome.
Inclusion Criteria for BECTS participants
Diagnosis: Child has newly diagnosed BECTS according to International League Against
Epilepsy (ILAE) criteria (including normal EEG background for age, at least 1 partial onset
seizure, and unilateral or bilateral central/mid-temporal sharp waves with a positive
horizontal dipole).
Age: The child's age is between 5 years, 0 months and 13 years, 11 months at study entry.
Language: The child must be a monolingual native speaker of English.
Handedness : The child must be right-handed.
Females: females of child bearing potential must agree to an acceptable and non-systemic
form of birth control (including abstinence).
Intelligence: The child must have clinician-judged normal intelligence.
Academic History: The child must have an academic history of a regular education program
(i.e., not in a special education class or program) without repeating grades.
Parent/Guardians:
- The patient's parent/guardian must be able to keep an accurate seizure record.
- Informed consent from the child's parent or legal guardian.
- Parents (guardians) must be able and willing to comply with instructions and study
procedures.
Assent: Assent from the child if age 11 years or older.
Demographic characteristics: Children will be between 7 and < 14 years old at the time of
enrollment. Children of both sexes and all race/ethnicities will be enrolled.
Exclusion Criteria for BECTS participants
Clinical Contraindications
- Children with diagnosis of Benign Occipital Epilepsy (BOE - normal EEG background, and
unilateral or bilateral occipital sharp waves activated by eye closure).
- Children with history of primary generalized seizures (absence, myoclonic, drop).
- Children with mixed seizure disorder (e.g., Lennox-Gastaut Syndrome).
- Children sensory seizures only (i.e., auras).
- Children with diagnoses of pervasive developmental disorders (e.g., autism/autism
spectrum disorders).
- Children with progressive neurological disease (e.g., degenerative, progressive
neoplasm).
- Children with major medical disease (e.g., IDDM, depression, suicide attempt. cancer,
renal failure).
- Children with a history of neonatal seizures.
Pregnancy: Children who are pregnant will not be eligible for enrollment.
Prior Therapy
- Children previously or currently treated with an AED for any reason (other than non
chronic benzodiazepine, e.g., ED treatment).
- Children taking any psychoactive agent other than psychostimulants for ADD/ADHD.
- Children taking a psychostimulant for ADD/ADHD and not on a stable dose for at least 2
weeks at time of study enrollment.
MRI
• Standard MRI exclusion criteria, e.g. orthodontic braces, cochlear implant or other
metallic implants which obscure or interfere with the MRI.
Special Education: Children with a special education placement based on ability or
behavior.
Informed Consent: Inability or unwillingness of child or legal guardian/representative to
give written informed consent.
Child not fluent in English.
Inclusion Criteria for Healthy Controls
Language: The child must be a monolingual native speaker of English.
Handedness: The child must be right-handed.
Females: Females of child bearing potential must agree to an acceptable and non-systemic
form of birth control (including abstinence).
Intelligence: The child must have clinician-judged normal intelligence.
Academic History: The child must have an academic history of a regular education program
(i.e., not in a special education class or program) without repeating grades.
Parents/Guardians:
- Informed consent from the child's parent or legal guardian.
- Parents (guardians) must be able and willing to comply with instructions and study
procedures.
Assent: Assent from the child if age 11 years or older.
Demographic characteristics: Children will be between 5 and < 14 years old at the time of
enrollment. Children of both sexes will be enrolled and no child will be excluded on the
basis of race/ethnicity.
Exclusion Criteria for Healthy Controls
Clinical Contraindications
- Children with a diagnosis of a chronic neurological disorder.
- Children with diagnoses of pervasive developmental disorders (e.g., autism/autism
spectrum disorders).
- Children with progressive neurological disease (e.g., degenerative, progressive
neoplasm).
- Children with major medical disease (e.g., IDDM, cancer, renal failure).
- Children with a history of neonatal seizures.
- Pregnancy: Children who are pregnant will not be eligible for enrollment.
Prior Therapy
- Children previously or currently treated with an AED for any reason (other than non
chronic benzodiazepine, e.g., ED treatment).
- Children taking any psychoactive agent other than psychostimulants for ADD/ADHD.
- Children taking a psychostimulant for ADD/ADHD and not on a stable dose for at least 2
weeks at time of study enrollment.
MRI and MRI/EEG Abnormality
• Standard MRI exclusion criteria, e.g. orthodontic braces, cochlear implant or other
metallic implants which obscure or interfere with the MRI.
Special Education: Children with a special education placement based on ability or
behavior.
Informed Consent: Inability or unwillingness of child or legal guardian/representative to
give written informed consent.
Child not fluent in English.
We found this trial at
1
site
Click here to add this to my saved trials
